JWC

Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care

Retrieved on: 
Tuesday, March 12, 2024
Diabetes, Chronic venous insufficiency, Patient, Mouth ulcer, Journal, JWC, Wound healing, Safety, CVI, Trial of the century

The study, a real-world, multicenter, retrospective clinical study, analyzed 18 hard-to-heal wounds in 11 patients who received Dermacyte Matrix between August 2022 and August 2023.

Key Points: 
  • The study, a real-world, multicenter, retrospective clinical study, analyzed 18 hard-to-heal wounds in 11 patients who received Dermacyte Matrix between August 2022 and August 2023.
  • All the patients in the study had failed to respond favorably to prior standard of care wound treatment.
  • The findings from this multicenter clinical study have been published in the March addition of the peer reviewed Journal of Wound Care (JWC).
  • Merakris also will present a poster at the JWC- sponsored CAMPs (Cellular Acellular and Matrix-Like Products) Wound Care Summit in Miami, Florida, March 13-14.

RestorixHealth Welcomes Dr. William H. Tettelbach as New Chief Medical Officer

Retrieved on: 
Thursday, July 13, 2023
Research, Nursing, Surgery, Medical Supplies, Hospitals, Other Health, Managed Care, General Health, Health, Science, Newton, CWSP, Duke University, Medical Affairs Bureau, Intermountain Health, Monika Boehm-Tettelbach, Western University, FACP, Quality of life, Undersea and Hyperbaric Medical Society, Health informatics, MiMedx, Multimedia, Infection, CMO, 13th Waffen Mountain Division of the SS Handschar (1st Croatian), JWC, FIDSA, Medical director, MD, Patient, Outline of health sciences, Internal medicine, Mountain Division, HCA Healthcare, Hyperbaric medicine, Wound healing, Hospital, Podiatry

RestorixHealth, the nation’s leading wound care solutions company, has announced that Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO).

Key Points: 
  • RestorixHealth, the nation’s leading wound care solutions company, has announced that Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO).
  • He comes to RestorixHealth from HCA Healthcare, where he served as the Executive Medical Director, Wound & Hyperbaric Medicine Services for the Mountain Division.
  • View the full release here: https://www.businesswire.com/news/home/20230713335918/en/
    Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO) of RestorixHealth.
  • Dr. Tettelbach lends his expertise to numerous professional societies, committees and associations and has co-authored numerous research articles and book chapters.

IM Cannabis Reschedules Fourth Quarter and Full Year 2021 Conference Call to Thursday, March 31 at 9:00 a.m. ET

Retrieved on: 
Tuesday, March 29, 2022
Company, Pharmacy, Quality control, NASDAQ, Growth, Cannabis, Ecosystem, JWC, Patient, CSE, Drug

A recording of the conference call will also be available on the events & presentations section of the IM Cannabis investor relations website linked here .

Key Points: 
  • A recording of the conference call will also be available on the events & presentations section of the IM Cannabis investor relations website linked here .
  • IM Cannabis (NASDAQ: IMCC, CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers.
  • IM Cannabis is one of the very few companies with operations in Israel, Germany and Canada, the three largest federally legal markets.
  • In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH ("Adjupharm"), where it also distributes cannabis to pharmacies serving medical cannabis patients.

IM Cannabis to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 30 at 9:00 a.m. ET

Retrieved on: 
Wednesday, March 23, 2022
Company, Pharmacy, Quality control, NASDAQ, Growth, Cannabis, Ecosystem, JWC, Patient, CSE, Drug

A recording of the conference call will also be available on the events & presentations section of the IM Cannabis investor relations website linked here .

Key Points: 
  • A recording of the conference call will also be available on the events & presentations section of the IM Cannabis investor relations website linked here .
  • IM Cannabis (NASDAQ: IMCC, CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers.
  • IM Cannabis is one of the very few companies with operations in Israel, Germany and Canada, the three largest federally legal markets.
  • In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH ("Adjupharm"), where it also distributes cannabis to pharmacies serving medical cannabis patients.

CMS Corporation Announces Customized Mechanical Solutions LLC.

Retrieved on: 
Tuesday, February 1, 2022
JWC, CMS, Company, HVAC, Heat, Federation, Compass, Multimedia, SQI, 2009 Davis Cup, Construction, Heating, ventilation, and air conditioning

BARGERSVILLE, Ind., Feb. 1, 2022 /PRNewswire/ -- Customized Mechanical Solutions LLC (CMS LLC), a part of the CMS Corporation (CMS) Group of Companies, is a vertically integrated global mechanical building systems contractor headquartered in Bargersville, IN.

Key Points: 
  • BARGERSVILLE, Ind., Feb. 1, 2022 /PRNewswire/ -- Customized Mechanical Solutions LLC (CMS LLC), a part of the CMS Corporation (CMS) Group of Companies, is a vertically integrated global mechanical building systems contractor headquartered in Bargersville, IN.
  • CMS Corporation is pleased to add Customized Mechanical Solutions LLC, to its group of companies, which also includes SQI LLC, ACCIONA CMS JV, JWC CMS JV II, Compass CMS JV and various other joint ventures.
  • CMS Chairman/CEO, Ernest Enrique, stated, "We are very proud to introduce Customized Mechanical Solutions LLC.
  • About Customized Mechanical Solutions LLC: CMS LLC is a vertically integrated global mechanical building systems contractor headquartered in Bargersville, Indiana.

Patriot Battery Metals Provides Update on the Ongoing Drill Program at the Corvette-FCI Property, James Bay, QC

Retrieved on: 
Friday, October 15, 2021
Lithium, PGE, Program, FSE, Lac, CV5, Laboratory, CV6, GLOBE, NWT, Acquisition, Awareness, CSE, Property, Pontax River, Company, Board, Corvette, Social media, National Instrument 43-101, Quartz, COVID-19, JWC, CV, Marketing, News, SMS, National instrument, Management

A total of four (4) NQ size diamond drill holes (~758 m) have now been completed at the CV5 (3 holes) and CV6 (1 hole) pegmatites.

Key Points: 
  • A total of four (4) NQ size diamond drill holes (~758 m) have now been completed at the CV5 (3 holes) and CV6 (1 hole) pegmatites.
  • Sample processing is continuing, with the first two drill holes having been shipped for analysis to Activation Laboratories in Ancaster, ON.
  • The Maven-Cu-Au-Ag Trend hosts numerous mineralized showings and prospects over a more than 10 km long corridor across the Property.
  • About Patriot Battery Metals Inc.
    Patriot Battery Metals Inc. is a mineral exploration company focused on the acquisition and development of mineral projects containing battery, base and precious metals.

Patriot Battery Metals Comments on Recent Market Activity

Retrieved on: 
Friday, October 1, 2021
Lithium, Public relations, News, Marketing, OTCQB, JWC, Person, NWT, Corvette, CSE, PGE, FSE, Board, Pontax River, Acquisition, Company, Program, LLC, Awareness, OTC Markets Group, Industry, GLOBE, Mobile phone, Security (finance)

VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Patriot Battery Metals Inc. (the Company or Patriot) (CSE: PMET) (OTCQB: RGDCF) (FSE: R9GA) wishes to make the following statements regarding recent market activity concerning its common shares (the Common Shares) traded on the OTCQB marketplace.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Patriot Battery Metals Inc. (the Company or Patriot) (CSE: PMET) (OTCQB: RGDCF) (FSE: R9GA) wishes to make the following statements regarding recent market activity concerning its common shares (the Common Shares) traded on the OTCQB marketplace.
  • The Company believes that the promotion may have had some impact on market activity, but that a recent stock price increase and trading activity are due primarily to the Companys news released on September 16 and September 23, 2021 related to its drilling program.
  • The Company engaged JWC Marketing Awareness Group Inc. (JWC) on August 15, 2021 for the purpose of corporate marketing and investor awareness.
  • About Patriot Battery Metals Inc.
    Patriot Battery Metals Inc. is a mineral exploration company focused on the acquisition and development of mineral projects containing battery, base and precious metals.

Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Advanced Treatment Using Skin Substitute Products for Lower Extremity Diabetic Ulcers (LEDUs)

Retrieved on: 
Tuesday, August 17, 2021
Center, Industry, Standard of care, DFU, Journal, University, Centers for Medicare & Medicaid Services, Quality of life, Amputation, GLOBE, Regenerative medicine, CMS, Medical Affairs Bureau, SALSA, Osteomyelitis, Diabetes, Sterilization, Research, Tissue, AT, Medicine, Health, Ledu, Keck School of Medicine of USC, Infection, Allotransplantation, Ulcer, Risk, Good tissue practice, Patient, NAT, Caregiver, Advance healthcare directive, JWC, Ministry of Education (Malaysia), Hospital, Pharmaceutical industry

MARIETTA, Ga., Aug. 17, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced publication of its peer-reviewed study in the Journal of Wound Care (JWC), addressing the observed impact of Advanced Treatment (AT) using all high-cost skin substitute products in lower extremity diabetic ulcers (LEDUs) based on data from the Medicare Limited Dataset (October 1, 2015 through October 2, 2018). The study assessed outcome in patients receiving AT with all high-cost skin substitute products, as designated by the Centers for Medicare and Medicaid Services (CMS), for LEDUs versus No Advanced Treatment (NAT), and found that AT use could lead to a 42% reduction in major and minor amputations and all related costs, compared to NAT. Further, the study highlights preferable outcomes when AT follows parameters for use (FPFU), underscoring the importance of early treatment with regular intervals and well-defined treatment guidelines.

Key Points: 
  • Further, the study highlights preferable outcomes when AT follows parameters for use (FPFU), underscoring the importance of early treatment with regular intervals and well-defined treatment guidelines.
  • In 2018, an estimated three million Americans suffered from diabetic foot ulcers (DFUs) a type of LEDU.
  • The immediate physical and economic toll on people with diabetic lower extremity complications, including amputations, have been correlated to an increased five-year mortality rate.
  • We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process.

cbdMD Signs Exclusive Agreement to Enter Israeli Market with IM Cannabis Corp.

Retrieved on: 
Monday, August 9, 2021
Retail, Other Health, Pharmaceutical, Physical Therapy, Managed Care, Other Consumer, General Health, Other Natural Resources, Online Retail, Other Retail, Natural Resources, Specialty, Alternative Medicine, Consumer, Health, Medical Supplies, IMC, U.S. Securities and Exchange Commission, Sale, CSE, Beauty, Social media, Private Securities Litigation Reform Act, Skin, Annual report, JWC, Partnership, Serum, Review, Pharmacy, NASDAQ, NYSE, SEC, Patient, Stock, Aeroponics, Deloitte, Association, Risk, Marketing, Cannabidiol, Letter, MCO, Security (finance), Instagram, Company, EU, Pharmaceutical industry, Drug

We are excited to enter this partnership with an industry leader, cbdMD, and to extend their brand into the Israeli market.

Key Points: 
  • We are excited to enter this partnership with an industry leader, cbdMD, and to extend their brand into the Israeli market.
  • Upon the legalization of CBD products in Israel, the Israeli CBD market is expected to reach up to US$475 million by 2025a.
  • We are excited to partner with IM Cannabis Corp and to enter the Israeli market.
  • Over the past decade, the Company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market.